FDA Mandates PCCP Template for AI Ultrasound Submissions

On June 20, 2026, a new FDA submission requirement takes effect for AI-enabled ultrasound software as a medical device, replacing the 2024 guidance with a new template that makes preset change control planning, algorithm performance degradation monitoring, and real-world data feedback interface design a mandatory part of new submissions. For developers, compliance teams, procurement functions, and service partners involved in AI ultrasound products, this is worth close attention because it changes what must be prepared at the documentation and review stage before market access work can move forward.

What the new FDA template now requires

The FDA released the AI/ML-enabled Ultrasound Devices Premarket Submission Template v2.1 on June 13, 2026. According to the provided event summary, the template applies to newly submitted AI ultrasound SaMD, including products used for fetal biometry, cardiac ejection fraction estimation, and liver fat quantification.

The confirmed change is that these new submissions must include three elements: a Preset Change Control Plan (PCCP), an algorithm performance degradation monitoring mechanism, and a description of the real-world data feedback interface design. The template becomes effective on June 20, 2026, and replaces the 2024 version.

Where the practical pressure is likely to appear first

For product developers and filing teams

From an industry perspective, the immediate impact is likely to fall on submission preparation. Companies developing AI ultrasound SaMD may need to organize technical files around the new template structure rather than relying on document packages aligned with the 2024 guidance. The main pressure point is not only model performance description, but also whether change planning, monitoring logic, and feedback interface design are documented in a form suitable for premarket review.

For procurement and project delivery functions

Observably, procurement and delivery teams may also feel the effect when new product launches or update schedules depend on regulatory submission timing. If a planned submission package is not aligned with the new mandatory template after June 20, internal delivery milestones, customer onboarding plans, or implementation schedules could require adjustment. What deserves closer attention is the completeness of technical documentation and review-readiness of supporting materials before external commitments are made.

For testing, compliance, and supporting service providers

Testing, regulatory consulting, and compliance support roles may need to adjust their work around the new required content. The change suggests that support work may increasingly involve verifying whether monitoring mechanisms and real-world data feedback design are clearly represented in submission materials. In practical terms, document review scope, technical evidence preparation, and handoff quality between software, clinical, and regulatory teams may become more important.

What companies should review now

Check whether submission files still follow the replaced version

Analysis shows that one of the most immediate tasks is to identify whether any ongoing or upcoming AI ultrasound SaMD submission is still structured around the 2024 guidance. If so, companies should review whether the file set needs to be reorganized to fit the new mandatory template effective June 20.

Focus on PCCP and monitoring content as filing essentials

It is more appropriate to understand this change as a documentation threshold for new submissions, not merely as a formatting update. Companies should therefore pay close attention to whether their submission materials can clearly present the PCCP, the mechanism for detecting algorithm performance degradation, and the design description for real-world data feedback interfaces.

Recheck internal coordination across technical and regulatory teams

Because the required content spans change control, ongoing performance observation, and feedback interface design, companies may need tighter coordination between software development, regulatory affairs, quality, and post-market support functions. The event summary does not provide detailed enforcement practice, so this should be treated as a compliance preparation point rather than a confirmed execution outcome.

Watch downstream document and customer-facing impacts

Where submission readiness influences external timelines, businesses may also want to review technical appendices, bid materials, product specification packages, and customer delivery commitments for consistency. Analysis shows that the key risk is less about public messaging and more about whether upstream compliance documents are complete enough to support downstream procurement and delivery activity.

Why this reads as an execution signal rather than a general policy message

Observably, this update is not just a broad policy direction. It comes with a named template, a defined effective date, and a clear replacement of the 2024 version. That makes it more appropriate to understand the development as an execution-stage signal for new AI ultrasound submissions.

At the same time, analysis shows that the market still needs to watch how the template is applied in practice. The provided information confirms what must be included, but it does not describe detailed review expectations, common deficiencies, or how consistently filing teams and support providers will interpret the new requirements in early implementation.

How this update is best understood at this stage

At this stage, the most balanced reading is that the FDA has moved the discussion of AI ultrasound submission controls into a more operational requirement set for new filings. The immediate significance lies in submission preparation, compliance documentation, and coordination across technical and regulatory workflows. It should not yet be overstated as a confirmed market outcome, but it is already concrete enough to treat as a near-term compliance and delivery consideration for affected products.

About the basis of this article

This article is generated from the user-provided news title, event date, and event summary. Source types commonly relevant to developments of this kind include official regulatory announcements, regulator-issued submission templates or guidance documents, standards organization materials, industry association updates, and reporting by authoritative trade media.

No specific official source link was provided in the input, so the exact official link still requires further verification. Observably, follow-up attention should remain on implementation details, review interpretation, documentation expectations, bid or procurement document changes, industry feedback, and how affected companies adjust their submission and delivery practices after the June 20 effective date.